Home » Stocks » VRTX

Vertex Pharmaceuticals, Inc. (VRTX)

Stock Price: $216.50 USD -1.37 (-0.63%)
Updated November 24, 4:00 PM EST - Market closed
After-hours: $218.63 +2.13 (0.98%) Nov 24, 7:52 PM

Stock Price Chart

Key Info

Market Cap 56.30B
Revenue (ttm) 5.99B
Net Income (ttm) 2.69B
Shares Out 260.04M
EPS (ttm) 10.20
PE Ratio 21.23
Forward PE 18.90
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 24
Last Price $216.50
Previous Close $217.87
Change ($) -1.37
Change (%) -0.63%
Day's Open 215.66
Day's Range 215.13 - 219.47
Day's Volume 2,179,767
52-Week Range 197.47 - 306.08

More Stats

Market Cap 56.30B
Enterprise Value 50.69B
Earnings Date (est) Feb 3, 2021
Ex-Dividend Date n/a
Shares Outstanding 260.04M
Float 259.74M
EPS (basic) 10.36
EPS (diluted) 10.20
FCF / Share 11.44
Dividend n/a
Dividend Yield n/a
Earnings Yield 4.71%
FCF Yield 5.29%
Payout Ratio n/a
Shares Short 2.92M
Short Ratio 1.10
Short % of Float 1.12%
Beta 0.78
PE Ratio 21.23
Forward PE 18.90
P/FCF Ratio 18.90
PS Ratio 9.40
PB Ratio 6.88
Revenue 5.99B
Operating Income 2.68B
Net Income 2.69B
Free Cash Flow 2.98B
Net Cash 5.60B
Net Cash / Share 21.55
Gross Margin 31.05%
Operating Margin 44.67%
Profit Margin 44.90%
FCF Margin 49.73%
ROA 17.78%
ROE 40.20%
ROIC 101.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (28)

Buy 20
Overweight 2
Hold 6
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$287.84*
(32.95% upside)
Low
220
Current: $216.50
High
356
Target: 287.84
*Average 12-month price target from 25 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue4,1633,0482,4891,7021,0325801,2121,5271,411143
Revenue Growth36.59%22.46%46.2%64.89%77.86%-52.11%-20.63%8.25%883.91%-
Gross Profit3,6152,6382,2141,4929085191,0821,2471,330131
Operating Income1,2026351239.94-467-692-61046.73114-696
Net Income1,1772,097263-112-556-739-445-10729.57-755
Shares Outstanding257254249245241235225212205200
Earnings Per Share4.518.091.04-0.46-2.31-3.14-1.98-0.500.14-3.77
EPS Growth-44.25%677.88%--------
Operating Cash Flow1,5691,270845236-365-573-60.67268144-635
Capital Expenditures-75.45-95.52-99.42-56.56-45.30-51.20-51.39-71.14-34.60-38.05
Free Cash Flow1,4941,175746180-411-624-112197109-673
Cash & Equivalents3,8083,1682,0891,4821,1431,3961,4651,4231,0551,066
Total Debt539582606841826825507697456537
Net Cash / Debt3,2702,5871,482642317571958726599529
Assets8,3186,2463,5462,8972,4992,3352,3192,7592,2041,725
Liabilities2,2331,8111,5041,5591,4051,2389631,5251,2391,221
Book Value6,0854,4352,0291,1579401,0751,356999787504
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Vertex Pharmaceuticals, Inc.
Country United States
Employees 3,000
CEO Reshma Kewalramani

Stock Information

Ticker Symbol VRTX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: VRTX
IPO Date July 24, 1991

Description

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics. The company was founded in 1989 and is headquartered in Boston, Massachusetts.